Trametinib | JTP-74057 | MEK Inhibitor | AmBeed-信号通路专用抑制剂

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

Cell Line DLD1 HCT116 CRC cells SW480 cells BBN963 cells BBN963 cells KRAS-mutant mouse lung cancer cells KRAS-mutant human lung cancer cells KRAS-wild type human lung cancer cells TBP primary melanoma cells S462 cells	Concentration	Treated Time	Description	References
DLD1	1 μM	24 hours	PD318088 increased TCF-Wnt reporter levels and expression of AXIN2 in DLD1.	Nat Commun. 2019 May 16;10(1):2197.
HCT116	1 μM	24 hours	PD318088 increased TCF-Wnt reporter levels and expression of AXIN2 in HCT116.	Nat Commun. 2019 May 16;10(1):2197.
CRC cells	25 nM	5 days	To evaluate the effect of Trametinib in combination with JQ1 on CRC cell colony formation, results showed that the combination almost completely abolished the colony-forming ability of CRC cells	Clin Cancer Res. 2017 Apr 15;23(8):2027-2037.
SW480 cells	50 nM	2 days	To evaluate the effect of Trametinib in combination with JQ1 on MYC protein expression in SW480 cells, results showed that the combination significantly reduced MYC protein levels	Clin Cancer Res. 2017 Apr 15;23(8):2027-2037.
BBN963 cells	100 µM	72 h	To evaluate the apoptosis-inducing effect of Trametinib on BBN963 cells, results showed that Trametinib alone led to increased numbers of cells in late apoptosis.	Nat Commun. 2024 Aug 2;15(1):6538.
BBN963 cells	100 µM	72 h	To evaluate the apoptosis-inducing effect of combined Rosiglitazone and Trametinib treatment on BBN963 cells, results showed that the combined treatment further increased the percentage of cells in both early and late apoptosis.	Nat Commun. 2024 Aug 2;15(1):6538.
KRAS-mutant mouse lung cancer cells	100 nM	72 h	To evaluate the effect of Trametinib on the growth of KRAS-mutant mouse lung cancer cells, results showed that Trametinib significantly inhibited cell growth.	Mol Cancer. 2024 Apr 20;23(1):78.
KRAS-mutant human lung cancer cells	500 nM	72 h	To evaluate the effect of Trametinib on the growth of KRAS-mutant human lung cancer cells, results showed that Trametinib significantly inhibited cell growth.	Mol Cancer. 2024 Apr 20;23(1):78.
KRAS-wild type human lung cancer cells	500 nM	72 h	To evaluate the effect of Trametinib on the growth of KRAS-wild type human lung cancer cells, results showed that Trametinib did not significantly affect cell growth.	Mol Cancer. 2024 Apr 20;23(1):78.
TBP primary melanoma cells	1 nM	10 days	To evaluate the effect of Trametinib on melanoma spheroids, results showed that Trametinib inhibited spheroid growth.	Cancer Res. 2023 Jul 14;83(14):2328-2344.
S462 cells	200 nM	24 h	To evaluate the anti-proliferative activity of Trametinib on MPNST cells, results showed that Trametinib combined with Palbociclib significantly reduced RB1 phosphorylation levels.	Clin Cancer Res. 2023 Sep 1;29(17):3484-3497.

Species CD-1 nude mice Nude mice Mice Mouse Mice Mice NOD-SCID mice Mice	Animal Model A375 melanoma tumor model Subcutaneous CRC xenograft model BBN-induced BASQ bladder cancer model KRAS-mutant lung cancer model Pancreatic cancer model TBP melanoma model QGP-1 xenograft model MPNST PDX model	Administration	Dosage	Frequency	Description	References
CD-1 nude mice	A375 melanoma tumor model	Oral	0.3 mg/kg or 1 mg/kg	Siremadlin: qdx3 (every 3 days); Trametinib: qdx6 (every 6 days)	To evaluate the antitumor effects of Siremadlin and Trametinib alone and in combination in an A375 melanoma tumor model. Results showed significantly higher tumor growth inhibition when used in combination compared to monotherapy.	Int J Mol Sci. 2022 Oct 26;23(21):12984.
Nude mice	Subcutaneous CRC xenograft model	Oral	0.5 mg/kg or 1 mg/kg	Once daily for 14 days	To evaluate the effect of Trametinib in combination with JQ1 on subcutaneous CRC xenograft tumors, results showed that the combination significantly reduced tumor volume	Clin Cancer Res. 2017 Apr 15;23(8):2027-2037.
Mice	BBN-induced BASQ bladder cancer model	Oral	0.3 mg/kg	Daily for one month	To evaluate the effect of Trametinib alone on BBN-induced BASQ tumors, results showed that Trametinib alone reduced tumor proliferation but did not completely eliminate tumors.	Nat Commun. 2024 Aug 2;15(1):6538.
Mouse	KRAS-mutant lung cancer model	Oral	1 mg/kg	5 times a week for 30 days	To evaluate the effect of Trametinib on tumor growth in KRAS-mutant lung cancer mouse models, results showed that Trametinib significantly reduced tumor volume.	Mol Cancer. 2024 Apr 20;23(1):78.
Mice	Pancreatic cancer model	Oral	1 mg/kg	Four consecutive days, followed by 3 days off treatment	To evaluate the therapeutic effect of Trametinib in a pancreatic cancer model	Nat Cancer. 2022 Nov;3(11):1367-1385
Mice	TBP melanoma model	Oral	1 mg/kg	Daily for 5 weeks	To evaluate the therapeutic effect of Trametinib on melanoma, results showed that Trametinib significantly inhibited tumor growth and delayed the onset of resistance.	Cancer Res. 2023 Jul 14;83(14):2328-2344.
NOD-SCID mice	QGP-1 xenograft model	Oral	1 mg/kg	Twice a week for 2 weeks	To evaluate the effect of Trametinib on the invasion capability of PTEN-knockdown QGP-1 xenograft tumors, results showed that Trametinib significantly suppressed tumor invasion.	J Biomed Sci. 2022 Nov 6;29(1):92
Mice	MPNST PDX model	Oral	0.075 mg/kg	Once daily for 5 days, off for 2 days	To evaluate the anti-tumor activity of Trametinib combined with Ribociclib on MPNST PDX models, results showed that the combination therapy significantly slowed tumor growth.	Clin Cancer Res. 2023 Sep 1;29(17):3484-3497.

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03225664	Lung Diseases Due to External ... 展开 >>Agents Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	May 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations CR_Study_Registration@mdanderson.org 收起 <<
NCT02872259	Melanoma	Phase 1 Phase 2	Recruiting	March 2020	Norway ... 展开 >> Haukeland University Hospital Recruiting Bergen, Norway, 5021 Contact: Oddbjørn Straume, MD, PhD oddbjorn.straume@helse-bergen.no Akershus Univerisity Hospital Not yet recruiting Lørenskog, Norway, 1478 Contact: Jürgen Geisler, MD, PhD Jurgen.geisler@ahus.no Oslo University Hospital, Radiumhospitalet Recruiting Oslo, Norway, 0424 Contact: Marta Nyakas, MD, PhD marta.nyakas@ous.no University Hospital of North Norway Recruiting Tromsø, Norway, 9038 Contact: Anita Amundsen, MD Anita.amundsen@unn.no St. Olavs Hospital Recruiting Trondheim, Norway, 7006 Contact: Jarle Karlsen, MD Jarle.Karlsen@stolav.no 收起 <<
NCT02039947	Melanoma and Brain Metastases	Phase 2	Completed	-	-
NCT01721603	-		Terminated(Low accrual)	-	-
NCT02684058	Diffuse Astrocytoma ... 展开 >> Anaplastic Astrocytoma Astrocytoma Oligodendroglioma, Childhood Anaplastic Oligodendroglioma Glioblastoma Pilocytic Astrocytoma Giant Cell Astrocytoma Pleomorphic Xanthoastrocytoma Anaplastic Pleomorphic Xanthoastrocytoma Angiocentric Glioma Chordoid Glioma of Third Ventricle Gangliocytoma Ganglioglioma Anaplastic Ganglioglioma Dysplastic Gangliocytoma of Cerebrellum Desmoplastic Infantile Astrocytoma and Ganglioglioma Papillary Glioneuronal Tumor Rosette-forming Glioneurona Tumor Central Neurocytoma Extraventricular Neurocytoma Cerebellar Iponeurocytoma 收起 <<	Phase 2	Recruiting	September 13, 2024	-
NCT01721603	BRAFV600E Melanoma Patients	Phase 2	Terminated(Low accrual)	-	United States, California ... 展开 >> University of San Francisco, California San Francisco, California, United States, 94115 收起 <<
NCT01902173	Adult Solid Neoplasm ... 展开 >> Recurrent Colon Carcinoma Recurrent Melanoma Recurrent Ovarian Carcinoma Stage IIIC Colon Cancer Stage IIIC Ovarian Cancer Stage IIIC Skin Melanoma Stage IV Skin Melanoma 收起 <<	Phase 1 Phase 2	Suspended(Temporarily stopped ... 展开 >>for assessment. Contact ctsucontact@westat.com for specifics) 收起 <<	-	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 California Pacific Medical Center-Pacific Campus San Francisco, California, United States, 94115 UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, Colorado University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Oregon Clackamas Radiation Oncology Center Clackamas, Oregon, United States, 97015 Providence Milwaukie Hospital Milwaukie, Oregon, United States, 97222 Providence Newberg Medical Center Newberg, Oregon, United States, 97132 Providence Willamette Falls Medical Center Oregon City, Oregon, United States, 97045 Providence Portland Medical Center Portland, Oregon, United States, 97213 Providence Saint Vincent Medical Center Portland, Oregon, United States, 97225 Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Washington PeaceHealth Southwest Medical Center Vancouver, Washington, United States, 98664 收起 <<
NCT02382549	Melanoma	Phase 1 Phase 2	Recruiting	June 2020	United States, Virginia ... 展开 >> Cancer Center at the University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 收起 <<
NCT03704688	Non Small Cell Lung Cancer ... 展开 >> KRAS Gene Mutation 收起 <<	Phase 1 Phase 2	Recruiting	April 2021	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Kathryn Arbour, MD 646-449-1775 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Kathryn Arbour, MD 646-449-1775 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Kathryn Arbour, MD 646-449-1775 Memorial Sloan Kettering @ Rockville Recruiting Rockville Centre, New York, United States, 11570 Contact: Kathryn Arbour, MD 646-449-1775 收起 <<
NCT02281760	BRAF V600E Mutation	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01248858	Cancer	Phase 1	Terminated(The reason for term... 展开 >>ination was lack of tolerability and efficacy of the combination treatment) 收起 <<	-	United States, North Carolina ... 展开 >> GSK Investigational Site Chapel Hill, North Carolina, United States, 27599-7305 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Canada, Ontario GSK Investigational Site Toronto, Ontario, Canada, M5G 2M9 Italy GSK Investigational Site Milano, Lombardia, Italy, 20132 收起 <<
NCT01912625	KRAS Activating Mutation ... 展开 >> Recurrent Non-Small Cell Lung Carcinoma Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 收起 <<	Phase 1	Active, not recruiting	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT01584648	Melanoma	Phase 3	Active, not recruiting	October 15, 2018	-
NCT01584648	-		Active, not recruiting	-	-
NCT02152995	BRAF Gene Mutation ... 展开 >> Poorly Differentiated Thyroid Gland Carcinoma RAS Family Gene Mutation Recurrent Thyroid Gland Carcinoma Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 收起 <<	Phase 2	Recruiting	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alan L. Ho 646-888-4235 hoa@mskcc.org Principal Investigator: Alan L. Ho 收起 <<
NCT01336634	Cancer	Phase 2	Active, not recruiting	December 1, 2020	-
NCT02416232	-		-	-	France ... 展开 >> GSK Investigational Site Amiens Cedex, France, 80054 GSK Investigational Site Angers, France, 49100 GSK Investigational Site Bayonne cedex, France, 64109 GSK Investigational Site Besancon cedex, France, 25030 GSK Investigational Site Bobigny, France, 93000 GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Boulogne-Billancourt, France, 92100 GSK Investigational Site Brest cedex, France, 29609 GSK Investigational Site Caen Cedex 9, France, 14033 GSK Investigational Site Chambray-Les-Tours, France, 37170 GSK Investigational Site Clermont-Ferrand cedex 1, France, 63003 GSK Investigational Site Creteil, France, 94010 GSK Investigational Site Dijon Cedex, France, 21079 GSK Investigational Site Grenoble cedex 9, France, 38043 GSK Investigational Site La Rochelle cedex 1, France, 17019 GSK Investigational Site Le Havre, France, 76083 GSK Investigational Site Le Mans, France, 72000 GSK Investigational Site Lille, France, 59037 GSK Investigational Site Limoges cedex, France, 87042 GSK Investigational Site Lorient, France, 56322 GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Marseille Cedex 5, France, 13385 GSK Investigational Site Montpellier cedex 5, France, 34295 GSK Investigational Site Montpellier Cedex 5, France, 34298 GSK Investigational Site Mulhouse, France, 68100 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Nice, France, 06202 GSK Investigational Site Nimes, France, 30029 cedex 9 GSK Investigational Site Orleans Cedex 2, France, 45067 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris, France, 75006 GSK Investigational Site Pau, France, 64000 GSK Investigational Site Pierre-Benite cedex, France, 69495 GSK Investigational Site Poitiers, France, 86021 GSK Investigational Site Pringy Cedex, France, 74374 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Rouen, France, 76031 GSK Investigational Site Saint-Pierre, France, 97448 GSK Investigational Site Saint-Priest en Jarez, France, 42270 GSK Investigational Site Strasbourg Cedex, France, 67091 GSK Investigational Site Thionville, France, 57126 Cedex 1 GSK Investigational Site Toulouse Cedex 9, France, 31059 GSK Investigational Site Valence Cedex 9, France, 26953 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 GSK Investigational Site Villejuif cedex, France, 94805 收起 <<
NCT02910700	BRAF Gene Mutation ... 展开 >> BRAF wt Allele Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 2	Recruiting	December 31, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Hussein A. Tawbi 713-792-2921 Principal Investigator: Hussein A. Tawbi 收起 <<
NCT01943864	Cancer	Phase 2	Completed	-	Japan ... 展开 >> GSK Investigational Site Chiba, Japan, 277-8577 GSK Investigational Site Osaka, Japan, 537-8511 GSK Investigational Site Shizuoka, Japan, 411-8777 GSK Investigational Site Tokyo, Japan, 104-0045 GSK Investigational Site Tokyo, Japan, 181-8611 收起 <<
NCT02357732	Metastatic Melanoma	Phase 1	Withdrawn(PI decided not to pr... 展开 >>oceed) 收起 <<	-	-
NCT01336634	-		Active, not recruiting	-	-
NCT01723202	Follicular Thyroid Cancer ... 展开 >> Insular Thyroid Cancer Papillary Thyroid Cancer Recurrent Thyroid Cancer 收起 <<	Phase 2	Active, not recruiting	December 31, 2019	United States, California ... 展开 >> University of California, San Diego San Diego, California, United States, 92093-0698 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital, Harvard Medical School Boston, Massachusetts, United States, 02114 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Texas The University of Texas-MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02367859	Ameloblastoma ... 展开 >> BRAF Gene Mutation 收起 <<	Phase 2	Recruiting	August 2020	United States, California ... 展开 >> Stanford University, School of Medicine Recruiting Stanford, California, United States, 94305 Contact: Elizabeth Winters 650-721-6509 ewinters@stanford.edu Principal Investigator: Alexander D. Colevas Sub-Investigator: Jonathan Pollack Sub-Investigator: Davud Sirjani Sub-Investigator: Robert West 收起 <<
NCT02027961	Melanoma	Phase 1 Phase 2	Completed	-	United States, Arizona ... 展开 >> Research Site Scottsdale, Arizona, United States, 85258 United States, California Research Site Los Angeles, California, United States, 90095 Research Site San Francisco, California, United States, 94143 United States, Florida Research Site Miami Beach, Florida, United States, 33140 United States, Illinois Research Site Chicago, Illinois, United States, 60611 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02114 United States, Missouri Research Site Saint Louis, Missouri, United States, 63110 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Research Site Montreal, Quebec, Canada, H3A 1A1 France Research Site Villejuif cedex, France, 94805 Italy Research Site Napoli, Italy, 80131 收起 <<
NCT01943864	-		Completed	-	-
NCT01658553	Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> GSK Investigational Site San Antonio, Texas, United States, 78229 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112 收起 <<
NCT02399943	Colorectal Cancer ... 展开 >> KRAS Wildtype NRAS Wildtype BRAF Wildtype 收起 <<	Phase 2	Recruiting	December 2020	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada Contact: Philippe Bedard, M.D. 416-946-4534 Philippe.Bedard@uhn.ca 收起 <<
NCT02143050	Melanoma	Phase 1 Phase 2	Recruiting	June 2020	United States, Kentucky ... 展开 >> James Graham Brown Cancer Center-Universityof Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Jason A Chesney, MD, PhD 502-562-3429 jason.chesney@louisville.edu Contact: Christina LaDuke 502-217-5205 christy.laduke@louisville.edu Sub-Investigator: Donald M Miller, MD, PhD Sub-Investigator: Kelly M McMasters, MD, PhD Sub-Investigator: Sucheta Telang, MD James Graham Brown Cancer Center Recruiting Louisville, Kentucky, United States, 40202 Contact: Karen Carter, BSN 502-562-3690 kmcart05@louisville.edu Contact: Christina LaDuke, BS 502-217-5205 christi.laduke@louisville.edu 收起 <<
NCT02065063	Cancer	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 收起 <<
NCT01979523	Recurrent Uveal Melanoma ... 展开 >> Stage IV Uveal Melanoma AJCC v7 收起 <<	Phase 2	Completed	-	United States, Georgia ... 展开 >> Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, New York Columbia University/Herbert Irving Cancer Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 France Institut Curie Paris Paris, France, 75005 United Kingdom The University of Liverpool Liverpool, United Kingdom, L69 3GA 收起 <<
NCT02196181	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma 收起 <<	Phase 2	Recruiting	-	-
NCT02314143	Melanoma	Phase 2	Completed	-	France ... 展开 >> GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Marseille cedex 5, France, 13385 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Villejuif cedex, France, 94805 Spain GSK Investigational Site Barcelona, Spain, 08036 GSK Investigational Site Madrid, Spain, 28041 收起 <<
NCT02016729	Advanced Malignancy ... 展开 >> Cancer Oncology Oncology Patients Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> Research Site Birmingham, Alabama, United States, 35294 United States, New York Research Site Buffalo, New York, United States, 14263 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Utah Research Site Salt Lake City, Utah, United States, 84112 United States, Washington Research Site Seattle, Washington, United States, 98101 收起 <<
NCT03543306	Cancer Lung C... 展开 >>ancer Metastatic BRAF V600E 收起 <<	Phase 2	Recruiting	June 30, 2022	Korea, Republic of ... 展开 >> Asan Medical Center Recruiting Seoul, Korea, Republic of, 138-736 Contact: Sang-We Kim, M.D. 82-2-3010-3215 swkim@amc.seoul.kr Principal Investigator: Sang-We Kim, M.D. 收起 <<
NCT03026517	Melanoma	Phase 1	Recruiting	January 2020	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Keith Flaherty, MD 617-724-4800 United States, New York Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Paul Chapman, MD 646-888-4162 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Paul Chapman, MD 646-888-4162 Contact: Michael Postow, MD 646-888-4589 Principal Investigator: Paul Chapman, MD 收起 <<
NCT01935973	Endometrial Adenocarcinoma ... 展开 >> Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Recurrent Uterine Corpus Carcinoma 收起 <<	Phase 1	Active, not recruiting	-	-
NCT02231775	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 收起 <<	Phase 2	Recruiting	October 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jennifer Wargo 713-745-1553 Principal Investigator: Jennifer Wargo 收起 <<
NCT01938443	Cancer	Phase 1	Completed	-	France ... 展开 >> GSK Investigational Site Villejuif Cedex, France, 94805 United Kingdom GSK Investigational Site London, United Kingdom, W12 0HS GSK Investigational Site London, United Kingdom, W1G 6AD GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN 收起 <<
NCT03087071	Colorectal Cancer	Phase 2	Recruiting	December 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact evilar@mdanderson.org 收起 <<
NCT02967692	Melanoma	Phase 3	Recruiting	February 13, 2020	-
NCT01907815	Recurrent Adult Acute Myeloid ... 展开 >>Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Terminated(Lack of efficacy.)	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02079740	Advanced Malignant Solid Neopl... 展开 >>asm KRAS Gene Mutation Metastatic Malignant Solid Neoplasm NRAS Gene Mutation Recurrent Colorectal Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Colorectal Cancer AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Malignant Neoplasm 收起 <<	Phase 1 Phase 2	Recruiting	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Suspended Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ryan B. Corcoran 877-726-5130 Principal Investigator: Ryan B. Corcoran 收起 <<
NCT01907815	-		Terminated(Lack of efficacy.)	-	-
NCT02258607	Relapsed Metastatic KRAS-Mutat... 展开 >>ed Non-Small Cell Lung Cancer 收起 <<	Phase 1	Terminated	-	United States, California ... 展开 >> Duarte, California, United States Sacramento, California, United States United States, Massachusetts Boston, Massachusetts, United States United States, Virginia Fairfax, Virginia, United States United States, Washington Spokane, Washington, United States 收起 <<
NCT02230553	Colorectal Cancer	Phase 1 Phase 2	Recruiting	December 2019	Netherlands ... 展开 >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066CX Contact: N HM Steeghs, MD, PhD 0031205122446 n.steeghs@nki.nl 收起 <<
NCT02642042	KRAS Gene Mutation ... 展开 >> Recurrent Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer AJCC v7 收起 <<	Phase 2	Active, not recruiting	October 15, 2020	-
NCT03317119	RAS Family Gene Mutation ... 展开 >> Stage III Colon Cancer AJCC v7 Stage III Colorectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7 Stage IIIA Colon Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIA Rectal Cancer AJCC v7 Stage IIIB Colon Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIB Rectal Cancer AJCC v7 Stage IIIC Colon Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IIIC Rectal Cancer AJCC v7 Stage IV Colon Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Rectal Cancer AJCC v7 Stage IVA Colon Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVA Rectal Cancer AJCC v7 Stage IVB Colon Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Stage IVB Rectal Cancer AJCC v7 收起 <<	Phase 1	Recruiting	December 2019	United States, California ... 展开 >> City of Hope Corona Recruiting Corona, California, United States, 92879 Contact: Cheryl Corpus 626-256-4673 ext 81529 Principal Investigator: Misagh Karimi, MD City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Marwan Fakih, MD 626-256-4673 mfakih@coh.org Principal Investigator: Marwan Fakih, MD City of Hope Antelope Valley Recruiting Lancaster, California, United States, 93534 Contact: Regan Johnson 626-256-4673 ext 25648 Principal Investigator: Mohammad Fekrazad, MD City of Hope Mission Hills Recruiting Mission Hills, California, United States, 91345 Contact: Amy Shousha 626-256-4673 ext 81865 Principal Investigator: Suzy Melkonian, MD City of Hope Rancho Cucamonga Recruiting Rancho Cucamonga, California, United States, 91730 Contact: Valerie Estala 626-256-4673 ext 81699 Principal Investigator: Behnam Ebrahimi, MD City of Hope South Pasadena Recruiting South Pasadena, California, United States, 91030 Contact: Odessa Rodriguez 626-256-4673 ext 81409 Principal Investigator: Christina Yeon, MD City of Hope West Covina Recruiting West Covina, California, United States, 91790 Contact: Meizi Zheng 626-256-4673 ext 81336 Principal Investigator: Gargi Upadhyaya, MD 收起 <<
NCT01989598	Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Active, not recruiting	-	Canada, Alberta ... 展开 >> Foothills Hospital Calgary, Alberta, Canada, T2N 2T9 Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Kingston Health Sciences Centre Kingston, Ontario, Canada, K7L 2V7 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01989585	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 1 Phase 2	Recruiting	-	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Janice M. Mehnert United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: Kari L. Kendra United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Michael A. Davies 收起 <<
NCT03754179	Melanoma	Phase 1 Phase 2	Recruiting	December 1, 2020	Belgium ... 展开 >> UZ Brussel Recruiting Jette, Brabant, Belgium, 1090 Contact: Bart Neyns, Phd,Md 0032(0)2477 64 15 bart.neyns@uzbrussel.be Principal Investigator: Bart Neyns, Phd,Md 收起 <<
NCT02124772	Cancer	Phase 1	Recruiting	October 15, 2020	United States, Arizona ... 展开 >> Novartis Investigative Site Recruiting Phoenix, Arizona, United States, 85016-7710 United States, California Novartis Investigative Site Recruiting San Francisco, California, United States United States, Maryland Novartis Investigative Site Recruiting Baltimore, Maryland, United States, 21287 United States, Massachusetts Novartis Investigative Site Recruiting Boston, Massachusetts, United States, 02115 United States, Minnesota Novartis Investigative Site Recruiting Minneapolis, Minnesota, United States, 55455 United States, New York Novartis Investigative Site Recruiting New York, New York, United States, 10065 United States, Ohio Novartis Investigative Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Novartis Investigative Site Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Novartis Investigative Site Recruiting Memphis, Tennessee, United States, 38105-3678 United States, Washington Novartis Investigative Site Recruiting DC, Washington, United States, DC 20010 Australia, New South Wales Novartis Investigative Site Recruiting Westmead, New South Wales, Australia, 2145 Canada, Ontario Novartis Investigative Site Recruiting Toronto, Ontario, Canada, M5G 1X8 France Novartis Investigative Site Recruiting Paris Cedex 05, France, 75248 Novartis Investigative Site Recruiting Villejuif Cedex, France, 94805 United Kingdom Novartis Investigative Site Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Novartis Investigative Site Recruiting London, United Kingdom, WC1N 3JH 收起 <<
NCT01978236	-		Terminated(This study was term... 展开 >>inated due to the limited enrollment.) 收起 <<	-	-
NCT02292732	Cancer	Phase 1	Withdrawn	May 2017	-
NCT02097225	BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Malignant Solid Neoplasm Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Ryan J. Sullivan 617-724-4000 rsullivan7@partners.org Principal Investigator: Ryan J. Sullivan Dana-Farber Cancer Institute Suspended Boston, Massachusetts, United States, 02215 收起 <<
NCT01978236	Melanoma and Brain Metastases	Phase 2	Terminated(This study was term... 展开 >>inated due to the limited enrollment.) 收起 <<	-	United States, Pennsylvania ... 展开 >> GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site North Sydney, New South Wales, Australia, 2060 收起 <<
NCT02439411	-		Completed	-	Spain ... 展开 >> Complejo Hospitalario Torrecárdenas Almeria, Almería, Spain Hospital Universitario Son Espases Palma De Mallorca, Baleares, Spain Instituto Catalán de Oncología Badalona/Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain Instituto Catalán de Oncología L'Hospitalet L'Hospitalet De Llobregat, Barcelona, Spain Corporació Sanitaria Parc Taulí de Sabadell Sabadell, Barcelona, Spain Hospital Universitario Marqués de Valdecilla Santander, Cantabria, Spain Onkologikoa Fundazioa Donostia, Guipúzcoa, Spain Complejo Hospitalario Universitario Insular de Canarias Las Palmas de Gran Canaria, Las Palmas, Spain Clínica Universidad Navarra Pamplona, Navarra, Spain Hospital Universitario de Navarra Pamplona, Navarra, Spain Hospital Clínic de Barcelona Barcelona, Spain Hospital General Universitario de Elche Elche, Spain Instituto Catalán de Oncología Girona/Hospital Universitari Dr. Josep Trueta Girona, Spain Hospital Universitario San Cecilio Granada, Spain Hospital Universitari Arnau de Vilanova Lleida, Spain Hospital 12 de Octubre Madrid, Spain Hospital Universitaria La Princesa Madrid, Spain Hospital Universitario Gregorio Marañón Madrid, Spain Hospital Universitario La Paz Madrid, Spain Hospital Universitario Ramón y Cajal Madrid, Spain Hospital Regional Universitario de Málaga Málaga, Spain Complexo Hospitalario Universitario de Ourense Orense, Spain Hospital Universitario Central de Asturias Oviedo, Spain Hospital Universitario de Valme Sevilla, Spain Hospital Virgen de la Salud Toledo, Spain Hospital Clínico Universitario de Valencia Valencia, Spain Hospital General Universitario de Valencia Valencia, Spain Instituto Valenciano de Oncología Valencia, Spain Hospital Miguel Servet Zaragoza, Spain 收起 <<
NCT02974803	Melanoma Brai... 展开 >>n Metastases 收起 <<	Phase 2	Recruiting	June 2020	Canada, Nova Scotia ... 展开 >> QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane 902 473-6106 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Elaine McWhirter 905 387-9495 ext 64609 Odette Cancer Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Teresa M. Petrella 416 480-4662 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Anna Spreafico 416 946-4501 ext 4012 Canada, Quebec Centre hospitalier universitaire de Sherbrooke Recruiting Sherbrooke, Quebec, Canada, J1H 5N4 Contact: David Mathieu 819 346-1110 ext 14887 Canada, Saskatchewan Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Vijayananda Kundapur 306 655-2740 收起 <<
NCT02034110	Cancer	Phase 2	Active, not recruiting	June 29, 2020	-
NCT01767454	Solid Tumours	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site Los Angeles, California, United States, 90025 GSK Investigational Site San Francisco, California, United States, 94115 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02215 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New York GSK Investigational Site New York, New York, United States, 10065 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 收起 <<
NCT03091257	Multiple Myeloma	Phase 1	Recruiting	December 2021	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Noopur S. Raje, MD 617-726-3810 Principal Investigator: Noopur S. Raje, MD United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jeffery Zonder, MD 313-576-8673 zonderj@karmanos.org Principal Investigator: Jeffery Zonder, MD 收起 <<
NCT01725100	Cancer	Phase 1	Completed	-	United States, Arizona ... 展开 >> GSK Investigational Site Goodyear, Arizona, United States, 85338 GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Florida GSK Investigational Site Sarasota, Florida, United States, 34232 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 收起 <<
NCT02296112	Recurrent Melanoma ... 展开 >> Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma 收起 <<	Phase 2	Recruiting	January 2024	United States, District of Col... 展开 >>umbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Bridget Haley 202-687-6871 Principal Investigator: Suthee Rapisuwon, MD United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Keith T Flaherty, MD 617-724-4000 KFLAHERTY@mgh.harvard.edu Principal Investigator: Keith T. Flaherty, MD United States, New York Memorial Sloan-Kettering Cancer Center Withdrawn New York, New York, United States, 10021 United States, Pennsylvania University of Pennsylvania Cancer Center Withdrawn Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: B. VICC Clinical Trials Information Program 800-811-8480 Principal Investigator: Douglas B. Johnson, MD United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Anna Vardeleon 713-794-4274 asreckew@mdanderson.org Principal Investigator: Michael A. Davies, MD 收起 <<
NCT02342600	Gastrointestinal Stromal Tumor... 展开 >>s 收起 <<	Phase 2	Withdrawn(Supporting company w... 展开 >>ithdrew interest) 收起 <<	-	-
NCT03148275	Epithelioid Hemangioendothelio... 展开 >>ma Locally Advanced Epithelioid Hemangioendothelioma Metastatic Epithelioid Hemangioendothelioma 收起 <<	Phase 2	Recruiting	December 31, 2023	-
NCT03272464	Melanoma	Phase 1	Recruiting	September 30, 2023	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02214 Contact: Keith Flaherty, MD 617-724-4800 KFLAHERTY@mgh.harvard.edu Principal Investigator: Keith T. Flaherty, MD 收起 <<
NCT02296996	Malignant Melanoma	Phase 2	Active, not recruiting	December 2017	Belgium ... 展开 >> UZ Brussel Brussels, Belgium, 1090 收起 <<
NCT02538627	Colorectal Cancer ... 展开 >> Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck 收起 <<	Phase 1	Terminated(Sponsor decision)	-	United States, Colorado ... 展开 >> University of Colorado Aurora, Colorado, United States, 80045 United States, Georgia Northside Hospital Sandy Springs, Georgia, United States, 30342 United States, Illinois Northwestern Chicago, Illinois, United States, 60611 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, Tennessee Vanderbilt Nashville, Tennessee, United States, 37235 收起 <<
NCT02292173	Hepatocellular Cancer ... 展开 >> Liver Cancer 收起 <<	Phase 1	Active, not recruiting	April 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT02672358	Non-Small-Cell Lung Cancer	Phase 2	Withdrawn(Company Decision)	December 7, 2020	-
NCT02881242	Hormone-Resistant Prostate Can... 展开 >>cer Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer 收起 <<	Phase 2	Recruiting	January 31, 2021	United States, California ... 展开 >> UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90095 Contact: Matthew B. Rettig 310-794-3565 mrettig@mednet.ucla.edu Principal Investigator: Matthew B. Rettig 收起 <<
NCT03266159	Solid Tumours	Phase 2	Withdrawn(Study withdrawn befo... 展开 >>re active to fully evaluate impact of changing practice in target population.) 收起 <<	August 19, 2020	-
NCT03714958	Colorectal Cancer ... 展开 >> Advanced Cancer Metastatic Cancer 收起 <<	Phase 1	Not yet recruiting	November 2020	-
NCT03386071	-		-	-	-
NCT01682083	-		Active, not recruiting	-	-
NCT02580708	Non-small Cell Lung Cancer	Phase 1 Phase 2	Terminated(Discontinued develo... 展开 >>pment of rociletinib in NSCLC. Stopped enrollment of new patients into all studies involving rociletinib.) 收起 <<	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States, 28204 United States, Tennessee Tennessee Oncology, PLLC - The Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Virginia Virginia Cancer Specialists Fairfax, Virginia, United States, 22031 收起 <<
NCT01682083	Melanoma	Phase 3	Active, not recruiting	November 30, 2030	-
NCT02083354	Cancer	Phase 2	Active, not recruiting	December 20, 2019	China, Guangdong ... 展开 >> Novartis Investigative Site Guangzhou, Guangdong, China, 510060 China, Yunnan Novartis Investigative Site Kunming, Yunnan, China, 650106 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310022 China Novartis Investigative Site Beijing, China, 100036 Hong Kong Novartis Investigative Site Tuen Mun, Hong Kong Korea, Republic of Novartis Investigative Site Seoul, Korea, Republic of, 110-744 Novartis Investigative Site Seoul, Korea, Republic of, 120-752 Taiwan Novartis Investigative Site Kaohsiung, Taiwan, 807 Novartis Investigative Site Taipei, Taiwan, 100 Novartis Investigative Site Taoyuan County, Taiwan, 333 Thailand Novartis Investigative Site Bangkok, Thailand, 10320 Novartis Investigative Site Bangkok, Thailand, 10400 Novartis Investigative Site Songkla, Thailand, 90110 收起 <<
NCT02070549	Advanced Malignant Solid Neopl... 展开 >>asm Hepatic Complication Metastatic Malignant Neoplasm in the Liver Metastatic Malignant Solid Neoplasm Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Florida Moffitt Cancer Center Suspended Tampa, Florida, United States, 33612 United States, Illinois University of Chicago Comprehensive Cancer Center Active, not recruiting Chicago, Illinois, United States, 60637 United States, Michigan Wayne State University/Karmanos Cancer Institute Suspended Detroit, Michigan, United States, 48201 United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Benjamin R. Tan United States, New Jersey Rutgers Cancer Institute of New Jersey Active, not recruiting New Brunswick, New Jersey, United States, 08903 United States, Ohio Ohio State University Comprehensive Cancer Center Suspended Columbus, Ohio, United States, 43210 United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Vivek Subbiah Canada, British Columbia BCCA-Vancouver Cancer Centre Suspended Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Suspended Hamilton, Ontario, Canada, L8V 5C2 University Health Network-Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Site Public Contact 416-946-4501 clinical.trials@uhn.on.ca Principal Investigator: Lillian L. Siu 收起 <<
NCT01964924	Estrogen Receptor Negative ... 展开 >> HER2/Neu Negative Invasive Breast Carcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma 收起 <<	Phase 2	Active, not recruiting	-	United States, District of Col... 展开 >>umbia MedStar Georgetown University Hospital Washington, D.C., District of Columbia, United States, 20007 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02015117	Metastatic Malignant Neoplasm ... 展开 >>in the Brain 收起 <<	Phase 1	Active, not recruiting	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT03551626	Malignant Melanoma	Phase 3	Recruiting	October 22, 2021	-
NCT02447939	Melanoma	Phase 1	Withdrawn(Change in strategy)	December 2018	-
NCT02300935	Melanoma	Phase 1	Withdrawn(Study concept was te... 展开 >>rminated.) 收起 <<	November 2018	United States, Colorado ... 展开 >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Center Sarasota, Florida, United States, 34232 United States, Tennessee Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 收起 <<
NCT01740648	Recurrent Rectal Cancer ... 展开 >> Stage IIA Rectal Cancer Stage IIB Rectal Cancer Stage IIC Rectal Cancer Stage IIIA Rectal Cancer Stage IIIB Rectal Cancer Stage IIIC Rectal Cancer 收起 <<	Phase 1	Active, not recruiting	December 31, 2022	United States, Missouri ... 展开 >> Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States 收起 <<
NCT02140840	Multiple Myeloma	Phase 2	Withdrawn(PI left institution)	April 2016	United States, Arkansas ... 展开 >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 收起 <<
NCT02428270	Pancreatic Cancer ... 展开 >> Adenocarcinoma 收起 <<	Phase 2	Active, not recruiting	December 2018	Canada, Ontario ... 展开 >> Juravinski Cancer Center Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Centre London, Ontario, Canada The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02138292	Melanoma	Phase 1	Completed	-	United States, Texas ... 展开 >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT01726738	Stage III Melanoma ... 展开 >> Stage IV Melanoma Unresectable Melanoma BRAF Mutant Melanoma 收起 <<	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT03631953	Meningioma	Phase 1	Not yet recruiting	January 1, 2022	France ... 展开 >> Assistance Publique Hôpitaux de Marseille Not yet recruiting Marseille, France, 13354 Contact: Thomas GRAILLON, PH 491385545 ext +33 thomas.graillon@ap-hm.fr Contact: Olivier CHINOT, PU-PH 491385545 ext +33 olivier.chinot@ap-hm.fr Principal Investigator: Thomas GRAILLON, PH 收起 <<
NCT02705963	Solid Tumors	Phase 1	Recruiting	May 21, 2019	United States, Michigan ... 展开 >> Karmanos Cancer Institute Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact 313-576-8730 Principal Investigator: Amy M Weise Henry Ford Hospital Henry Ford Recruiting Detroit, Michigan, United States, 48202 2689 Contact 313-916-8862 Principal Investigator: Ding Wang United States, Oklahoma University of Oklahoma Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact 405-271-4022 Principal Investigator: Kathleen Moore Belgium Novartis Investigative Site Recruiting Edegem, Belgium, 2650 Novartis Investigative Site Recruiting Namur, Belgium, 5000 Novartis Investigative Site Recruiting Wilrijk, Belgium, 2610 Netherlands Novartis Investigative Site Recruiting Maastricht, Netherlands, 6202AZ Spain Novartis Investigative Site Recruiting Santiago de Compostela, Galicia, Spain, 15706 Novartis Investigative Site Recruiting Madrid, Spain, 28034 Novartis Investigative Site Recruiting Malaga, Spain, 29010 United Kingdom Novartis Investigative Site Recruiting London, United Kingdom, W1G 6AD 收起 <<
NCT01553851	-		Completed	-	-
NCT03668431	Metastatic Colorectal Cancer	Phase 2	Recruiting	March 1, 2021	United States, Massachusetts ... 展开 >> Massachusetts General Hosital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Ryan Corcoran, MD 617-724-4000 Principal Investigator: Ryan Corcoran, MD Dana Farber Cancer Institite Recruiting Boston, Massachusetts, United States, 02215 Contact: Marios Giannakis, MD 617-632-3000 MGIANNAKIS@PARTNERS.ORG Principal Investigator: Marios Giannakis, MD 收起 <<
NCT03076164	Lung Adenocarcinoma ... 展开 >> Lung Cancer Lung Cancer Metastatic Lung Cancer Stage IV Recurrent Lung Adenocarcinoma Recurrent Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	March 2020	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Helena Yu, MD 646-888-4274 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Helena Yu, MD 646-888-4274 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Helena Yu, MD 646-888-4274 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Helena Yu, MD 646-888-4274 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Helena Yu, MD 646-888-4274 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Helena Yu, MD 646-888-4274 Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Helena Yu, MD 646-888-4274 收起 <<
NCT01972347	Melanoma	Phase 2	Active, not recruiting	May 2022	Australia, New South Wales ... 展开 >> Melanoma Institute Australia North Sydney, New South Wales, Australia, 2060 收起 <<
NCT03741101	Neurofibromatosis 1 ... 展开 >> Child Neurofibroma, Plexiform 收起 <<	Phase 2	Recruiting	May 2022	Sweden ... 展开 >> Skåne University Hospital Recruiting Lund, Sweden, 22241 Contact: Björn Sigurdsson, MD 0046708253552 bjorn.sigurdsson@skane.se Contact: Erik A Eklund, MD, PhD 0046730785917 erik.eklund@skane.se 收起 <<
NCT01553851	Neoplasms, Oral ... 展开 >> Mouth Neoplasms 收起 <<	Phase 2	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT01958112	Cervical Cancer	Phase 2	Terminated(Drug supply)	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT03190915	Activating RAS Mutation ... 展开 >> Blasts Under 20 Percent of Bone Marrow Nucleated Cells Blasts Under 20 Percent of Peripheral Blood White Cells Juvenile Myelomonocytic Leukemia Monosomy 7 Neurofibromatosis Type 1 NF1 Gene Mutation PTPN11 Gene Mutation Splenomegaly 收起 <<	Phase 2	Recruiting	December 30, 2020	-
NCT03085056	Anaplastic Thyroid Cancer	Early Phase 1	Recruiting	March 2019	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Eric Sherman, MD 646-888-4234 Contact: David Pfister, MD 646-888-4237 Principal Investigator: Eric Sherman, MD 收起 <<
NCT03340506	Melanoma Non ... 展开 >>Small Cell Lung Cancer Solid Tumor Rare Cancers High Grade Glioma 收起 <<	Phase 4	Recruiting	July 17, 2023	United States, Arizona ... 展开 >> Honor Health Research Institute Recruiting Scottsdale, Arizona, United States, 85258 Contact: Kristina Will 623-238-7671 Kristina.Will@honorhealth.com Principal Investigator: Michael Gordon United States, Ohio James Cancer Hospital & Solove Research Institute-Ohio State Recruiting Columbus, Ohio, United States, 43210 Contact: Tomasina Wall 614-366-7421 Tomasina.Wall@osumc.edu Principal Investigator: Kari L. Kendra United States, Texas Mary Crowley Research Center Recruiting Dallas, Texas, United States, 75251 Contact: Christy Lacy 214-658-1941 clacy@marycrowley.org Principal Investigator: Minal Barve France Novartis Investigative Site Recruiting Paris, France, 75970 Spain Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Recruiting Madrid, Spain, 28040 Novartis Investigative Site Recruiting Madrid, Spain, 28050 收起 <<
NCT01941927	Melanoma	Phase 2	Unknown	May 2016	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, New York Memorial Sloan-Kettering Cancer Center New York City, New York, United States, 10065 收起 <<
NCT03516214	Bronchial Neoplasms	Phase 1	Recruiting	November 25, 2021	Germany ... 展开 >> University Hospital of Aachen Recruiting Aachen, Germany Contact: Christian Hasenbank +49 241 80 85490 chasenbank@ukaachen.de University Hospital of Cologne Recruiting Cologne, Germany Contact: Claudia Wömpner +49 221 478 84556 claudia.woempner@uk-koeln.de Contact: Gregor Zadoyan, Dr. +49 221 478 98766 gregor.zadoyan@uk-koeln.de University Hospital Essen Recruiting Essen, Germany Contact: Diana Cortés Incio +49 201 723 3155 diana.cortes-incio@uk-essen.de University Hospital Frankfurt Not yet recruiting Frankfurt, Germany Contact: Anne Oehler +49 69 6301 86431 ohler@med.uni-frankfurt.de University Hospital Würzburg Not yet recruiting Würzburg, Germany Spain Hospital Germany Trias y Pujol Not yet recruiting Badalona, Spain Vall d'Hebron University Hospital Not yet recruiting Barcelona, Spain 收起 <<
NCT03428126	Malignant Neoplasms of Digesti... 展开 >>ve Organs Colorectal Cancer Colon Cancer 收起 <<	Phase 2	Enrolling by invitation	November 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02939846	Cancer	Phase 1	Withdrawn(Change in strategy)	December 2018	-
NCT03232892	Non-small Cell Lung Cancer	Phase 2	Recruiting	September 22, 2021	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Contact: Collin Blakely, MD 877-827-3222 cancertrials@ucsf.edu 收起 <<
NCT03087448	Non-small Cell Lung Cancer	Phase 1 Phase 2	Recruiting	March 2021	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 收起 <<
NCT03363217	Low-grade Glioma ... 展开 >> Plexiform Neurofibroma Central Nervous System Glioma 收起 <<	Phase 1 Phase 2	Recruiting	December 1, 2026	Canada, Alberta ... 展开 >> Alberta Children's Hospital Not yet recruiting Calgary, Alberta, Canada, T3B 6A8 Contact: Lucie Lafay-Cousin, MD 1 403-955-2554 lucie.lafay-cousin@ahs.ca Contact: Pina Giuliano 1-403-955-7269 pina.giuliano@ahs.ca Principal Investigator: Lucie Lafay-Cousin, MD Canada, Ontario The Hospital for Sick Children Recruiting Toronto, Ontario, Canada, M5G 1X8 Contact: Ruben Machado, MSc (416) 813-7654 ext 203204 ruben.machado@sickkids.ca Principal Investigator: Eric Bouffet, MD Sub-Investigator: Uri Tabouri, MD Canada, Quebec CHU Sainte-Justine Recruiting Montreal, Quebec, Canada, H3T 1C5 Contact: Linda Hershon 1-(514)-345-4931 ext 5899 linda.hershon@recherche-ste-justine.qc.ca Principal Investigator: Sébastien Perreault, MD Montreal Children's Hospital Recruiting Montreal, Quebec, Canada, H4A 3J1 Contact: Genevieve Legault, MD 1-(514)-412-4466 genevieve.legault4@mcgill.ca Principal Investigator: Genevieve Legault, MD Sub-Investigator: Nada Jabado, MD CHU de Québec Recruiting Quebec City, Quebec, Canada, G1V 4G2 Contact: Pana Giannakouros, MSc 1(418) 525-4444 ext 71671 panagiota.giannak@crchudequebec.ulaval.ca Contact: Valerie Larouche, MD 1(418) 525-4444 Valerie.Larouche@mail.chudequebec.ca Principal Investigator: Valerie Larouche, MD 收起 <<
NCT03299088	KRAS Gene Mutation ... 展开 >> Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Recurrent Non-Squamous Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer AJCC v7 收起 <<	Phase 1	Recruiting	March 1, 2021	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Jonathan W. Riess 916-734-7771 jwriess@ucdavis.edu Principal Investigator: Jonathan W. Riess 收起 <<

产品名称	MEK ↓ ↑	MEK1 ↓ ↑	MEK1/2 ↓ ↑	MEK2 ↓ ↑	MEK5 ↓ ↑	其他靶点	纯度
Honokiol	✔						98%
Mirdametinib	++++ MEK, IC50: 0.33 nM						99%+
Binimetinib	+++ MEK, IC50: 12 nM						99%+
BI-847325		++ MEK1, IC50: 25 nM		+++ MEK2, IC50: 4 nM			99%+
U0126-EtOH		+ MEK1, IC50: 0.07 μM		++ MEK2, IC50: 0.06 μM			98%
GDC-0623		++++ MEK1, IC50: 0.13 nM					99%+
TAK-733		++++ MEK1, IC50: 3.2 nM					99%+
Trametinib		++++ MEK1, IC50: 0.92 nM		++++ MEK2, IC50: 1.8 nM			99%+
Selumetinib		+++ MEK1, Kd: 99 nM MEK1, IC50: 14 nM		+ MEK2, Kd: 530 nM			99%+
CI-1040		++ MEK1, IC50: 17 nM		++ MEK2, IC50: 17 nM			99%+
Myricetin		✔					98%
Refametinib		++ MEK1, IC50: 19 nM		++ MEK2, IC50: 47 nM			99%+
Cobimetinib		+++ MEK1, IC50: 4.2 nM					99%+
PD98059		+ MEK1, IC50: 2 μM					99%+
SL327		+ MEK1, IC50: 0.18 μM		+ MEK2, IC50: 0.22 μM		AP-1	98+%
PD318088			✔				99%
AZD8330			+++ MEK1/2, IC50: 7 nM				99%+
Pimasertib							98%
(E/Z)-BIX02189					++++ MEK5, IC50: 1.5 nM		99%+
(E/Z)-BIX02188					+++ MEK5, IC50: 4.3 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

靶点	MEK2 MEK2, IC50:1.8 nM MEK1 MEK1, IC50:0.92 nM
描述	Trametinib, also called as GSK1120212 or JTP-74057, can strongly inhibit MEK1/2 kinase activities with IC50 value of 0.92nM and 1.8nM, respectively, without inhibition on the other 98 kinases (measured by Raf-MEK-ERK cascade kinase assay) regardless of the isotype of Raf and MEK. Trametinib can inhibit constitutive ERK phosphorylation (downstream of MEK) in cell lines, while the effect on anti-proliferation differs. Among them, HT-29 and COLO205 cells with a constitutively active B-Raf mutant were most sensitive to trametinib while COLO320 DM cells bearing the wild-type gene in both B-Raf and K-Ras were found to be resistant to trametinib. Oral treatment of trametinib 1mg/kg daily for 14 days blocked the tumor increase almost completely in nude mice bearing the HT-29 xenografts^[1].Trametinib is indicated for the treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations detected by an FDA-approved test^[2].
作用机制	Trametinib binds to MEK1/2 and induces allosteric inhibition of MEK1/2 catalysis.^[3]

Dose	Mice: min = 0.3 mg/kg^[1], max = 2 mg/kg^[2]
Administration	p.o.

CAS号	871700-17-3
分子式	C₂₆H₂₃FIN₅O₄
分子量	615.39
SMILES Code	CC(NC1=CC=CC(N(C(C(C(N2C3CC3)=O)=C(NC4=CC=C(I)C=C4F)N5C)=C(C)C5=O)C2=O)=C1)=O
MDL No.	MFCD17215075

别名	JTP-74057; GSK1120212
运输	蓝冰
InChI Key	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
Pubchem ID	11707110

Trametinib/曲美替尼 {[allProObj[0].p_purity_real_show]}

Trametinib/曲美替尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Trametinib/曲美替尼质控信息

Trametinib/曲美替尼生物活性

Trametinib/曲美替尼细胞实验

Trametinib/曲美替尼动物实验

Trametinib/曲美替尼动物研究

Trametinib/曲美替尼临床研究

Trametinib/曲美替尼参考文献

Trametinib/曲美替尼实验方案

Trametinib/曲美替尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Trametinib/曲美替尼 {[allProObj[0].p_purity_real_show]}

Trametinib/曲美替尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Trametinib/曲美替尼 质控信息

Trametinib/曲美替尼 生物活性

Trametinib/曲美替尼 细胞实验

Trametinib/曲美替尼 动物实验

Trametinib/曲美替尼 动物研究

Trametinib/曲美替尼 临床研究

Trametinib/曲美替尼 参考文献

Trametinib/曲美替尼 实验方案

Trametinib/曲美替尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Trametinib/曲美替尼纯度/质量文件产品仅供科研

Trametinib/曲美替尼质控信息

Trametinib/曲美替尼生物活性

Trametinib/曲美替尼细胞实验

Trametinib/曲美替尼动物实验

Trametinib/曲美替尼动物研究

Trametinib/曲美替尼临床研究

Trametinib/曲美替尼参考文献

Trametinib/曲美替尼实验方案

Trametinib/曲美替尼技术信息